Study of fluoroquinolones resistance in rifampicin-resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes

Abstract

Background: China is a high-burden country for multidrug-resistant tuberculosis/rifampin-resistant tuberculosis (MDR/RR-TB). Fluoroquinolones (FQs) are key drugs for the treatment of patients with MDR/RR-TB. However, research on the resistance of FQs in Beijing is limited.

Methods: We collected clinical isolates from all patients with pulmonary TB in Beijing from January 2016 to December 2021, conducted drug-sensitivity tests and sequencing for levofloxacin (LFX) and moxifloxacin (MFX), and collected the treatment plans and outcomes of the patients.

Results: A total of 8512 clinical isolates were collected from patients with pulmonary TB, and 261 RR-TB strains were screened. The proportions of drug-sensitive and drug-resistant strains significantly differed by age group and treatment history. The rates of LFX and MFX resistance were 27.6% (72/261) and 36.4% (95/261), respectively. The detection rates of MDR-TB and pre-extensively drug-resistant TB (pre-XDR-TB) were 73.2% (191/261) and 36.4% (95/261), respectively, and the trends were significant (χ² trend = 9.995, p = 0.002; χ² trend = 12.744, p = 0.026). Among the 261 RR-TB strains, 14.9% (24/261) were sensitive to LFX but resistant to MFX. Among the four patients with LFX-resistant TB who received LFX treatment failed in three patients (Fisher's exact test, p = 0.009). The common mutation sites were 94 and 90 in gyrA. A novel mutation Ala90Ser was discovered.

Conclusions: FQs resistance trends in RR-TB patients in Beijing are striking. Strains showed incomplete cross-resistance to LFX and MFX. Testing for FQs resistance and developing a reasonable treatment plan are recommended. Attention should be given to the changing trends in MDR-TB and pre-XDR-TB.

Keywords

drug resistance / levofloxacin / moxifloxacin / mycobacterium tuberculosis / pre-XDR-TB

References

[1] World Health Organization. Global Tuberculosis Report 2023. World Health Organization; 2023.

[2] WHO. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment (2020).

[3] Technical Report on Critical Concentrations for Drug Susceptibility Testing of Medicines Used in the Treatment of Drug-Resistant Tuberculosis. World Health Organization; 2018.

[4] World Health Organization. Optimized Broth Microdilution Plate Methodology for Drug Susceptibility Testing of Mycobacterium Tuberculosis Complex. World Health Organization; 2022.

[5] Guoping L, Xinran L. Research on the influence of coordinated development strategy of Beijing-Tianjin-Hebei on Beijing's population scale control. J Hebei Univ Econ Bus. 2021; 42(3): 94-102.

[6] Technical Manual for Drug Susceptibility Testing of Medicines Used in the Treatment of Tuberculosis. Licence: CC BY-NC-SA 3.0 IGO.

[7] CLSI. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes. CLSI supplement M24S. 2nd ed. Clinical and Laboratory Standards Institute; 2023.

[8] World Health Organization. Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis. World Health Organization; 2021.

[9] Chinese Antituberculosis Association. Guidelines for chemotherapy of drug resistant tuberculosis. Chin J Antituberc. 2019; 41(10): 1025-1073.

[10] Zhao YL, Chen MT. Technical Guidelines for Tuberculosis Prevention and Control in China. Beijing: People's Medical Publishing House; 2021: 183-186.

[11] Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J InfectDis. 2011; 15(3): e211-e216.

[12] Shenjie T. Re evaluation of the application of fluoroquinolones in drug-resistant tuberculosis. Chinese J Tuber Respir Dis. 2014; 37(10): 727-729.

[13] World Health Organization. Global Tuberculosis Report 2021. World Health Organization; 2021.

[14] National Health Commission of the People's Republic of China. Report on the Management and Resistance Status of Antibiotics in China (2018). Peking Union Medical College Press; 2019.

[15] Wushouer H, Zhou Y, Zhang X, et al. Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement data. Antimicrob Resist Infect Control. 2020; 9(1): 53.

[16] Zhao Y, Xu S, Wang L, et al. National Survey of drug-resistant tuberculosis in China. N Engl J Med. 2012; 366: 2161-2170.

[17] Caihong X, Yanlin Z. To evaluate the tuberculosis prevention and control situation in China from the perspective of global tuberculosis report 2020. Chin J Infect Dis. 2021; 39(7): 392-397.

[18] Mamatha HG, Shanthi V. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India. J Glob Antimicrob Resist. 2018; 12: 5-10.

[19] Chuang PH, Wu MH, Fan SY, Lin KY, Jou R. Population-based drug resistance surveillance of multidrug-resistant tuberculosis in Taiwan, 2007-2014. PLoS One. 2016; 11(11): e0165222.

[20] Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016; 16(10): 1185-1192.

[21] Yin J, Zhang H, Gao Z, et al. Transmission of multidrug-resistant tuberculosis in Beijing, China: an epidemiological and genomic analysis. Front Public Health. 2022; 10: 1019198.

[22] Zheng H, He W, Jiao W, et al. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect Dis. 2021; 21(1): 330.

[23] Hameed HMA, Tan Y, Islam MM, et al. Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China. J Thorac Dis. 2019; 11(11): 4613-4625.

[24] Wang Q, Song Y, Pang Y, et al. Study on the cross-resistance among 5 different fluroquinolones in ofloxacin-resistant Mycobacterium tuberculosis isolates. Chin J Antituberc. 2014; 36(6): 453-457.

[25] Xia H, Zheng Y, Liu D, et al. Strong increase in Moxifloxacin ResistancWe rate among multidrug-resistant Mycobacterium tuberculosis isolates in China, 2007 to 2013. Microbiol Spectr. 2021; 9(3): e0040921.

[26] Huo F, Zhang F, Xue Y, et al. Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene. Int J Infect Dis. 2020; 92: 241-246.

[27] Ou X, Song Z, Zhao B, et al. Diagnostic efficacy of an optimized nucleotide MALDI-TOF-MS assay for anti-tuberculosis drug resistance detection. Eur J Clin Microbiol Infect Dis. 2024; 43(1): 105-114.

[28] Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother. 2014; 58(1): 364-369.

[29] Mokrousov I, Otten T, Manicheva O, et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother. 2008; 52(8): 2937-2939.

[30] Sirous M, Khosravi AD, Tabandeh MR, Salmanzadeh S, Ahmadkhosravi N, Amini S. Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis. Infect Drug Resist. 2018; 11: 1819-1829.

[31] Li M, Zhang Y, Wu Z, et al. Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study. Emerg Microbes Infect. 2024; 13(1): 2302837.

[32] Zhang ZG, Du CY, Zhang Q, et al. Analysis of the relationship between gyrA mutations and fluoroquinolone levels in Mycobacterium tuberculosis isolates from China. Chinese J Antitubercul. 2016; 38(9): 706-711.

[33] Miotto P, Tessema B, Tagliani E, et al. A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis. Eur Respir J. 2017; 50: 1701354.

[34] World Health Organization. Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance. World Health Organization; 2021.

[35] World Health Organization. Catalogue of Mutations in Mycobacterium tuberculosis Complex and their Association with Drug Resistance. 2nd ed. World Health Organization; 2023.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.